Skip to content

Diagnosis and Prognosis for Aortic Aneurysm aNd Dissection in Anzhen(DPANDA) Study

Diagnosis and Prognosis for Aortic Aneurysm aNd Dissection in Anzhen

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03233087
Enrollment
1500
Registered
2017-07-28
Start date
2014-03-01
Completion date
2028-12-31
Last updated
2024-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Aneurysm, Aortic Dissection

Brief summary

The registry study aims to determine serial biomarkers to diagnosis and prognosis of aortic aneurysm/aortic dissection.

Detailed description

The study aims to investigate the role of candidate biomarkers in the diagnosis and prognosis of AA and AD. In the diagnosis part, we begin with a discovery phase where individually matched case-control study. Patients within each disease outcomes (i.e. AD, AMI, PE, AA without AD and healthy controls) are age and sex matched and retrospectively included.In the prognosis part of the study, patients with confirmed AA and AD are enrolled. The primary outcome is the all-cause mortality based on the death certificates. The secondary outcome is the in-hospital mortality according to the patients'medical records.

Interventions

None listed

Sponsors

Beijing Luhe Hospital
CollaboratorOTHER
The First Affiliated Hospital of Dalian Medical University
CollaboratorOTHER
The First Hospital of Jilin University
CollaboratorOTHER
First Affiliated Hospital, Sun Yat-Sen University
CollaboratorOTHER
The General Hospital of Northern Theater Command
CollaboratorOTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
CollaboratorOTHER
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

Retrospective * All patients who were referred to the surgical service for evaluation and management of aortic dissection were included. Perspective * Patients with initial suspicion of having AAD were perspectively enrolled.

Exclusion criteria

Retrospective * Patients who received packed red blood cells, whole blood, or platelets less than 10 days before the blood sample was taken; * Patients with aortic trauma, pseudo aneurysm, history of heart failure, renal dysfunction, severe pulmonary diseases, or active cancer; * Patients who entered the hospital for checkups after surgery. Perspective * Patients in whom there is little or no suspicion of a life-threatening disease; * Patients with confirmed acute myocardial infarction,angina or pulmonary embolism * The symptoms were clearly not related to AD (e.g. pleurisy, pneumonia, acute abdominal diseases).

Design outcomes

Primary

MeasureTime frameDescription
Dignosis of each participantThese data is collected from the cases' medical record in an average of 6 month after the sample recruiting1. Patients with Aneurysm/Dissection had image information from ultrasound cardiograms and computed tomography to confirm the final diagnosis. 2. AMI if they had chest pain lasting \>20 min, diagnostic serial ECG changes comprising new pathological Q waves or ST-segment and T-wave changes, and a plasma creatine kinase-MB elevation greater than twice the normal level or cardiac troponin I (cTnI) level greater than 0.1 ng/mL. 3. Diagnosis of PE was confirmed by positive spiral computed tomography or pulmonary angiography, a high probability on ventilation perfusion scintigraphy, or a proximal deep vein thrombosis documented on compression ultrasonography or angiography.
Prognosis of each participantThese data is collected from the cases' medical record or during follow-up visit at 2-4 years after discharge.Prognosis information including all-cause mortality and in-hospital mortality.

Countries

China

Contacts

Primary ContactYuan Wang, PhD
wangyuan980510@163.com86-010-64456721
Backup ContactXue Wang, MD
snowlove_@126.com+86 010-64456721

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026